Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SERENA-2 oral AZD9833 versus fulvestrant in ER-positive, HER2-negative advanced breast cancer
MOH_2020-09-22_009292Phase 2Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of camizestrant and fulvestrant in breast cancer (4 arms), sponsored by AstraZeneca. Primary endpoint: Progression-free survival. Planned start Aug 2020; status: not yet recruiting.
02
Drugs
camizestrantfulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on MOH_2020-09-22_009292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-09-22_009292.